ATM and breast cancer: This indicates that heterozygote ATM GPV carriers have an approximately two-fold higher risk of developing BC than non-carriers (odds ratios = 2.10 and 1.82, respectively) [12,13], with an absolute BC lifetime risk of 15–40% [12,13,115,116].